Active Biotech's election committee appointed

Active Biotech's election committee appointed 
LUND, SWEDEN -- (Marketwire) -- 11/15/12 --  In accordance with a
decision made by the Annual General Meeting held on May 10, 2012, the
Election Committee shall comprise the representatives for the three
largest shareholders, as per end of September 2012, and the Chairman
the Board. 
For the 2013 Annual General Meeting, the Election Committee shall
propose Board
members and a Chairman of the Board, and fees to Board
members and auditors. The following individuals were appointed
representatives for the largest shareholders and, accordingly, are
members of the Election Committee: 
Johnny Sommarlund, MGA Holding Tomas Billing, Nordstjernan Martin
Bjaeringer, representing his own holding and Hajskaeret Invest AB 
Under the leadership of the Chairman of the Board, Mats Arnhoeg, the
Committee shall prepare proposals for the Board of Directors
that are to be presented to and decided upon at the Annual General
Meeting on May 15,

Lund, November 15, 2012
Active Biotech AB (publ)
Tomas Leanderson
President and CEO

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
with focus on autoimmune/inflammatory diseases and cancer. Projects in
pivotal phase
are laquinimod, an orally administered small molecule
with unique immunomodulatory properties for the treatment of multiple
sclerosis, TASQ for
prostate cancer and ANYARA primarily for the
treatment of renal cell cancer. In addition, laquinimod is in Phase
II development for Crohn's and Lupus. The company also has one
additional project in clinical development, the orally administered
compound 57-57 for Systemic Sclerosis. Please visit  for more information. 
Active Biotech's election committee appointed: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE 
Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Press spacebar to pause and continue. Press esc to stop.